



## **BeyondSpring to Host Fourth-Quarter and Full-Year 2018 Financial Results and Operational Update Conference Call on April 30, 2019**

April 24, 2019

NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- [BeyondSpring Inc.](#) (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report fourth-quarter and full-year 2018 financial results and host an operational and clinical update conference call on Tuesday, April 30, 2019, at 8:00 a.m. Eastern Time.

The conference call may be accessed by dialing 1-855-327-6837 (U.S.) or 1-631-891-4304 (international) and referencing conference ID 10006728. A live webcast will be available on BeyondSpring's website at [www.beyondspringpharma.com](http://www.beyondspringpharma.com) under "[Events & Presentations](#)" in the Investors section. An archived replay of the webcast will be available for 30 days.

### **About BeyondSpring**

BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring's lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to Plinabulin, including three immuno-oncology assets and a drug discovery platform using the ubiquitination degradation pathway. The Company also has a seasoned management team with many years of experience bringing drugs to the global market.

### **Cautionary Note Regarding Forward-Looking Statements**

This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring's most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

### **Contact:**

#### **Investor Relations:**

Stephen Kilmer  
646.274.3580

[stephen.kilmer@beyondspringpharma.com](mailto:stephen.kilmer@beyondspringpharma.com)

#### **Media Relations:**

Caitlin Kasunich / Kathryn Hunter  
KCSA Strategic Communications  
212.896.1241 / 212.896.1204

[ckasunich@kcsa.com](mailto:ckasunich@kcsa.com) / [khunter@kcsa.com](mailto:khunter@kcsa.com)

BeyondSpring, Inc.